Developer docs
API playgroundTry for free, no card

Search company profiles

Mablink Bioscience

Full company profile

uuid00028et

Namestring
Mablink Bioscience
Websiteurl
mablink.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mablink Bioscience is a French biotechnology company founded in 2018 and headquartered in Lyon, France, that develops next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, enabling targeted delivery of cancer-killing agents to tumor cells while minimizing damage to healthy tissues. The company's lead candidate is MBK-103, an ADC targeting solid tumors including ovarian cancer, which it was advancing toward clinical development as of its €31 million Series A funding round in October 2022.

The company operated a pre-commercial, pipeline-focused business model reliant on institutional capital rather than product sales. Across two funding rounds, Mablink raised approximately €35 million: a €4 million seed round in May 2021 led by Elaia Partners, and a €31 million Series A in October 2022 co-led by Sofinnova Partners and Mérieux Equity Partners with participation from existing investors. Its revenue model anticipated future one-time licensing income and eventual commercialization of ADC treatments, with no current product revenue.

Mablink's scientific leadership consisted of co-founder and CSO Warren Viricel and Chief Development Officer Frédérique Brune. Following its Series A, the company's operating status shifted to "acquired," with its web domain now redirecting to Eli Lilly and Company, indicating that Eli Lilly has absorbed Mablink and its ADC platform into its broader oncology portfolio.

Short descriptiontext

Mablink Bioscience is a Lyon-based biotechnology company that developed next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy, with a lead candidate MBK-103 for solid tumors including ovarian cancer. The company was acquired by Eli Lilly.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics, cancer drug development, targeted cancer therapy, biopharmaceutical pipeline
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1ADC Pipeline Development
TypeOne Time License
Description

Developing antibody-drug conjugate pipeline for cancer therapy with lead candidate MBK-103 targeting solid tumors including ovarian cancer. Revenue expected from clinical development and eventual commercialization of treatments.

sofinnovapartners.com
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mablink Bioscience is a French biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. Its pipeline centers on lead candidate MBK-103, an ADC designed to deliver cytotoxic agents directly to solid tumor cells, including ovarian cancer, while limiting damage to healthy tissue. The company was advancing MBK-103 toward clinical development with the support of a €31 million Series A round.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • €31M Series A funding secured for clinical development
Product overview1 text field

Mablink Bioscience is a French biotechnology company developing antibody-drug conjugates (ADCs) for cancer therapy. The company operates with a pipeline approach centered on its lead candidate MBK-103, an ADC targeting solid tumors including ovarian cancer. The company raised €31 million in Series A funding in October 2022 to advance MBK-103 to clinical trials and expand its ADC pipeline.

Product and service1 record
1MBK-103
CategoryOncology Therapeutics
Description

Lead antibody-drug conjugate (ADC) candidate being advanced toward clinical development for the treatment of solid tumors, including ovarian cancer. It is intended to selectively deliver a cytotoxic payload to cancer cells using an antibody-targeting approach.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC biotech with a pipeline of ADCs targeting solid tumors. Comparable to Mablink in product modality and oncology indication focus.

TypeDirect peer
Description

European (German) preclinical/early-clinical biotech developing next-generation ADCs with proprietary linker and payload chemistry. Closely comparable to Mablink as a European ADC technology platform player.

TypeBroad incumbent
Description

Global pharma leader in ADCs through Enhertu and Datroway (with AstraZeneca). Comparable as a dominant ADC player in the same therapeutic space Mablink targets.

TypeDirect peer
Description

ADC and immuno-oncology biotech developing antibody-drug conjugates and other targeted therapies for solid tumors. Comparable to Mablink in modality, oncology focus, and pipeline approach.

TypeBroad incumbent
Description

Acquired Seagen in 2023, making Pfizer a top-tier ADC incumbent. Comparable as a strategic acquirer in the ADC space and direct competitor in solid-tumor ADC development.

TypeBroad incumbent
Description

Global pharma that acquired Mablink Bioscience. Comparable as Mablink's strategic parent and a major oncology/ADC platform incumbent now integrating Mablink's technology and lead candidate.

TypeDirect peer
Description

German ADC biotech with proprietary payload technology (Amanitin-based ADCs). Comparable to Mablink as a European ADC platform developer.

TypeBroad incumbent
Description

Co-develops Enhertu and Datroway ADCs with Daiichi Sankyo, a leading pharma force in the ADC category. Comparable as a broad incumbent with major ADC assets in solid tumors.

TypeDirect peer
Description

Clinical-stage ADC biotech developing next-generation antibody-drug conjugates for cancer. Closely comparable to Mablink in therapeutic focus (oncology ADCs) and stage.

TypeDirect peer
Description

Pioneer in ADC technology with multiple approved ADC products (e.g., Elahere for ovarian cancer). Directly comparable to Mablink as an ADC-focused developer targeting solid tumors, and was itself acquired by AbbVie.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mablink Bioscience

Oncology Biopharmaceuticalsmablink.com

Mablink Bioscience is a Lyon-based biotechnology company that developed next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy, with a lead candidate MBK-103 for solid tumors including ovarian cancer. The company was acquired by Eli Lilly.

What Mablink Bioscience does

Mablink Bioscience is a French biotechnology company founded in 2018 and headquartered in Lyon, France, that develops next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, enabling targeted delivery of cancer-killing agents to tumor cells while minimizing damage to healthy tissues. The company's lead candidate is MBK-103, an ADC targeting solid tumors including ovarian cancer, which it was advancing toward clinical development as of its €31 million Series A funding round in October 2022.

The company operated a pre-commercial, pipeline-focused business model reliant on institutional capital rather than product sales. Across two funding rounds, Mablink raised approximately €35 million: a €4 million seed round in May 2021 led by Elaia Partners, and a €31 million Series A in October 2022 co-led by Sofinnova Partners and Mérieux Equity Partners with participation from existing investors. Its revenue model anticipated future one-time licensing income and eventual commercialization of ADC treatments, with no current product revenue.

Mablink's scientific leadership consisted of co-founder and CSO Warren Viricel and Chief Development Officer Frédérique Brune. Following its Series A, the company's operating status shifted to "acquired," with its web domain now redirecting to Eli Lilly and Company, indicating that Eli Lilly has absorbed Mablink and its ADC platform into its broader oncology portfolio.

Mablink Bioscience firmographics

Firmographics
Name
Mablink Bioscience
Website
https://mablink.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Mablink Bioscience is a Lyon-based biotechnology company that developed next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy, with a lead candidate MBK-103 for solid tumors including ovarian cancer. The company was acquired by Eli Lilly.
Ownership category
akta.pro rank

Mablink Bioscience industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Cancer drug development
  • Targeted cancer therapy
  • Biopharmaceutical pipeline

Where Mablink Bioscience is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Mablink Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. ADC Pipeline Development: Developing antibody-drug conjugate pipeline for cancer therapy with lead candidate MBK-103 targeting solid tumors including ovarian cancer. Revenue expected from clinical development and eventual commercialization of treatments.

Go-to-market motion1 record

Mablink Bioscience product offering

Product offering

Core offering

Mablink Bioscience is a French biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. Its pipeline centers on lead candidate MBK-103, an ADC designed to deliver cytotoxic agents directly to solid tumor cells, including ovarian cancer, while limiting damage to healthy tissue. The company was advancing MBK-103 toward clinical development with the support of a €31 million Series A round.

Product overview

Mablink Bioscience is a French biotechnology company developing antibody-drug conjugates (ADCs) for cancer therapy. The company operates with a pipeline approach centered on its lead candidate MBK-103, an ADC targeting solid tumors including ovarian cancer. The company raised €31 million in Series A funding in October 2022 to advance MBK-103 to clinical trials and expand its ADC pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • MBK-103 Lead antibody-drug conjugate (ADC) candidate being advanced toward clinical development for the treatment of solid tumors, including ovarian cancer. It is intended to selectively deliver a cytotoxic payload to cancer cells using an antibody-targeting approach.

Quantifiable outcome

  • €31M Series A funding secured for clinical development

Companies that use Mablink Bioscience

Customer profile

Segments1 record

Ideal customer profiles2 records

Mablink Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mablink Bioscience partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Mablink Bioscience competitors and assessment

Company assessment

Direct peers

  • ProfoundBio: Clinical-stage ADC biotech with a pipeline of ADCs targeting solid tumors. Comparable to Mablink in product modality and oncology indication focus.
  • Tubulis: European (German) preclinical/early-clinical biotech developing next-generation ADCs with proprietary linker and payload chemistry. Closely comparable to Mablink as a European ADC technology platform player.
  • Pyxis Oncology: ADC and immuno-oncology biotech developing antibody-drug conjugates and other targeted therapies for solid tumors. Comparable to Mablink in modality, oncology focus, and pipeline approach.
  • Heidelberg Pharma: German ADC biotech with proprietary payload technology (Amanitin-based ADCs). Comparable to Mablink as a European ADC platform developer.
  • Mersana Therapeutics: Clinical-stage ADC biotech developing next-generation antibody-drug conjugates for cancer. Closely comparable to Mablink in therapeutic focus (oncology ADCs) and stage.
  • ImmunoGen: Pioneer in ADC technology with multiple approved ADC products (e.g., Elahere for ovarian cancer). Directly comparable to Mablink as an ADC-focused developer targeting solid tumors, and was itself acquired by AbbVie.

Broad incumbents

  • Daiichi Sankyo: Global pharma leader in ADCs through Enhertu and Datroway (with AstraZeneca). Comparable as a dominant ADC player in the same therapeutic space Mablink targets.
  • Pfizer: Acquired Seagen in 2023, making Pfizer a top-tier ADC incumbent. Comparable as a strategic acquirer in the ADC space and direct competitor in solid-tumor ADC development.
  • Eli Lilly and Company: Global pharma that acquired Mablink Bioscience. Comparable as Mablink's strategic parent and a major oncology/ADC platform incumbent now integrating Mablink's technology and lead candidate.
  • AstraZeneca: Co-develops Enhertu and Datroway ADCs with Daiichi Sankyo, a leading pharma force in the ADC category. Comparable as a broad incumbent with major ADC assets in solid tumors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Mablink Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mablink Bioscience leadership team

Management profile

Number of profiles

Profiles2 records

Mablink Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mablink Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mablink Bioscience

What does Mablink Bioscience do?

Mablink Bioscience is a French biotechnology company developing next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. Its pipeline centers on lead candidate MBK-103, an ADC designed to deliver cytotoxic agents directly to solid tumor cells, including ovarian cancer, while limiting damage to healthy tissue. The company was advancing MBK-103 toward clinical development with the support of a €31 million Series A round.

When was Mablink Bioscience founded?

Mablink Bioscience was founded in 2018. It employs 11 to 50 people.

Where is Mablink Bioscience based?

Mablink Bioscience is headquartered in Lyon, France, in the Europe region.

How does Mablink Bioscience make money?

One revenue line is on record: ADC Pipeline Development.

Who are Mablink Bioscience's main competitors?

Direct peers on record are ProfoundBio, Tubulis, Pyxis Oncology, Heidelberg Pharma, Mersana Therapeutics and ImmunoGen. Broad incumbents are Daiichi Sankyo, Pfizer, Eli Lilly and Company and AstraZeneca.

Does Mablink Bioscience have an API?

No public API is recorded for Mablink Bioscience.

What industry is Mablink Bioscience in?

Mablink Bioscience's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooMablink Bioscience Enters an Agreement to be Acquired by LillyMablink Bioscience has entered into an agreement to be acquired by Eli Lilly and Company, a deal that reflects the potential of Mablink's PSARLink™ technology for developing antibody-drug conjugates. The transaction is currently subject to approval from the French Ministry of the Economy.GlobeNewswireMablink Bioscience Enters an Agreement to be Acquired by LillyMablink Bioscience has entered into an agreement to be acquired by Eli Lilly and Company, reflecting the potential of Mablink's PSARLink™ technology for developing antibody-drug conjugates. The transaction is currently pending approval from the French Ministry of the Economy.GlobeNewswireMablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical OfficerMablink Bioscience appointed Pejvack Motlagh, M.D., as Chief Medical Officer, reporting to CEO Jean-Guillaume Lafay. He will lead clinical development strategy and operations, including advancing its lead compound MBK-103 toward First-in-Human studies in 2024. Motlagh previously held senior oncology roles at Boehringer Ingelheim, GSK, Bristol-Myers Squibb, and AstraZeneca.GlobeNewswireMablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023Mablink Bioscience will present preclinical data for its ADC candidate MBK-103 at the AACR Annual Meeting 2023, including efficacy in mouse models and safety in non-human primates. The company plans to submit a clinical trial application in Q4 2023.Les Echos​Mablink lève 31 M€ auprès de Sofinnova et Mérieux pour lutter contre le cancerFrench biotech company Mablink Bioscience raised 31 million euros in a Series A funding round. The investment was co-led by Sofinnova Partners and Mérieux Equity Partners, joining existing shareholders to support the company's efforts in fighting cancer.Merieux-PartnersMablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity PartnersMablink Bioscience announced the closing of a €31 million Series A funding round to advance its lead antibody-drug conjugate candidate into clinical trials. The investment was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.SofinnovapartnersMablink Bioscience announces a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners — Sofinnova PartnersMablink Bioscience announced a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners to advance its lead candidate, MBK-103, into clinical development for solid tumors. The financing will support the company in building a pipeline of next-generation antibody-drug conjugates using its proprietary linker technology. This capital raise marks Mablink's transition into a clinical-stage biotech firm.The Pharma LetterMablink bags 31 million euros financing to advance ADC pipelineFrance’s Mablink Biosciences announced it has raised a 31 million-euro ($30 million) Series A funding round to advance its lead candidate into clinical trials. The capital will also be used to build a pipeline of antibody-drug conjugates (ADCs) using the company's proprietary platform technology.BioSpaceMablink Bioscience announces appointment of its Chief Development OfficerMablink Bioscience appointed Frédérique Brune as Chief Development Officer to oversee regulatory development of its lead ADC candidate MBK-103. Brune will lead scientific and preclinical teams, with a primary objective of completing IND operations. She previously held development leadership roles at Innate Pharma and LFB.Les EchosBiotech : Mablink Bioscience s’amorce avec 4 M€Mablink Bioscience secured a 4 million euro seed funding round to develop its pipeline of antibody-drug conjugates (ADCs) for cancer treatment. The investment, led by Elaia Partners and supported by Sofimac Innovation, Sham Innovation Santé, the Fournier-Majoie Foundation, Simba Santé, and Crédit Agricole Création, will fund the advancement of these therapies toward clinical development stages.